Scorpius Holdings, Inc. (SCPX)

USD 0.29

(-0.87%)

Operating Expenses Summary of Scorpius Holdings, Inc.

  • Scorpius Holdings, Inc.'s latest annual operating expenses in 2023 was 39.81 Million USD , down -11.95% from previous year.
  • Scorpius Holdings, Inc.'s latest quarterly operating expenses in 2024 Q2 was 6.79 Million USD , down -4.24% from previous quarter.
  • Scorpius Holdings, Inc. reported a annual operating expenses of 45.22 Million USD in annual operating expenses 2022, up 45.07% from previous year.
  • Scorpius Holdings, Inc. reported a annual operating expenses of 31.17 Million USD in annual operating expenses 2021, up 11.83% from previous year.
  • Scorpius Holdings, Inc. reported a quarterly operating expenses of 6.79 Million USD for 2024 Q2, down -4.24% from previous quarter.
  • Scorpius Holdings, Inc. reported a quarterly operating expenses of 13.48 Million USD for 2023 Q2, down -4.87% from previous quarter.

Annual Operating Expenses Chart of Scorpius Holdings, Inc. (2023 - 2015)

Historical Annual Operating Expenses of Scorpius Holdings, Inc. (2023 - 2015)

Year Operating Expenses Operating Expenses Growth
2023 39.81 Million USD -11.95%
2022 45.22 Million USD 45.07%
2021 31.17 Million USD 11.83%
2020 27.87 Million USD 25.71%
2019 22.17 Million USD -3.68%
2018 23.02 Million USD 58.72%
2017 14.5 Million USD 8.75%
2016 13.33 Million USD -36.21%
2015 20.9 Million USD 0.0%

Peer Operating Expenses Comparison of Scorpius Holdings, Inc.

Name Operating Expenses Operating Expenses Difference
AIM ImmunoTech Inc. 32.07 Million USD -24.129%
Ampio Pharmaceuticals, Inc. 9.26 Million USD -329.605%
Armata Pharmaceuticals, Inc. 11.64 Million USD -241.795%
Actinium Pharmaceuticals, Inc. 52 Million USD 23.433%
Azitra, Inc. 8.3 Million USD -379.57%
Can-Fite BioPharma Ltd. 8.93 Million USD -345.466%
Chromocell Therapeutics Corporation 6.86 Million USD -480.211%
Calidi Biotherapeutics, Inc. 28.99 Million USD -37.334%
CEL-SCI Corporation 31.47 Million USD -26.495%
iBio, Inc. 16.85 Million USD -136.169%
Lineage Cell Therapeutics, Inc. 33 Million USD -20.628%
MAIA Biotechnology, Inc. 20.18 Million USD -97.28%
Matinas BioPharma Holdings, Inc. 24.86 Million USD -60.147%
Navidea Biopharmaceuticals, Inc. 13.93 Million USD -185.795%
NovaBay Pharmaceuticals, Inc. 12.89 Million USD -208.697%
NanoViricides, Inc. 8.51 Million USD -367.534%
Oragenics, Inc. 5.45 Million USD -630.303%
BiomX Inc. 26.81 Million USD -48.489%
BiomX Inc. 26.81 Million USD -48.489%
Protalix BioTherapeutics, Inc. 32.05 Million USD -24.222%
Palatin Technologies, Inc. 34.67 Million USD -14.841%